Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from …

R Al Hamed, AH Bazarbachi, M Mohty - Bone marrow transplantation, 2020 - nature.com
Epstein-Barr virus (EBV) is a ubiquitous herpes virus that infects the majority of the
population worldwide. The virus can establish a lifelong latent infection in host B …

[HTML][HTML] HIV-1 remission and possible cure in a woman after haplo-cord blood transplant

J Hsu, K Van Besien, MJ Glesby, S Pahwa, A Coletti… - Cell, 2023 - cell.com
Previously, two men were cured of HIV-1 through CCR5Δ32 homozygous (CCR5Δ32/Δ32)
allogeneic adult stem cell transplant. We report the first remission and possible HIV-1 cure in …

Epstein–Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes

J Lindsay, J Othman, MR Heldman… - Current opinion in …, 2021 - journals.lww.com
With an increasing number of risk groups for developing EBV PTLD in HCT and SOT,
management strategies using prophylaxis or preemptive therapy remain standard of care …

Key aspects of the immunobiology of haploidentical hematopoietic cell transplantation

SHC Baumeister, B Rambaldi, RM Shapiro… - Frontiers in …, 2020 - frontiersin.org
Hematopoietic stem cell transplantation from a haploidentical donor is increasingly used
and has become a standard donor option for patients lacking an appropriately matched …

[HTML][HTML] Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study

LN Walti, C Mugglin, D Sidler, M Mombelli… - American Journal of …, 2021 - Elsevier
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ
transplantation (SOT). Most PTLD cases are associated with Epstein–Barr virus (EBV) …

Outcomes of HLA-mismatched HSCT with TCRαβ/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity

SH Lum, MH Albert, P Gilbert, T Sirait, M Algeri… - Blood, 2024 - ashpublications.org
HLA-mismatched transplants with either in vitro depletion of CD3+ T-cell receptor (TCR)
αβ/CD19 (TCRαβ) cells or in vivo T-cell depletion using posttransplant cyclophosphamide …

Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell …

A Marjanska, J Styczynski - Expert Opinion on Biological Therapy, 2023 - Taylor & Francis
Introduction Post-transplant lymphoproliferative disorders (PTLD) represent a diverse group
of diseases. They develop as a consequence of uncontrolled proliferation of lymphoid or …

Post-transplant lymphoproliferative disease (PTLD) after allogeneic hematopoietic stem cell transplantation: biology and treatment options

M Clerico, I Dogliotti, A Aroldi, C Consoli… - Journal of Clinical …, 2022 - mdpi.com
Post-transplant lymphoproliferative disease (PTLD) is a serious complication occurring as a
consequence of immunosuppression in the setting of allogeneic hematopoietic stem cell …

[HTML][HTML] Predictors of COVID-19 vaccination response after in-vivo T-cell–depleted stem cell transplantation

O Chaekal, A Gomez-Arteaga, Z Chen, R Soave… - … and Cellular Therapy, 2022 - Elsevier
Covid-19 vaccination is recommended in allogeneic transplant recipients, but many
questions remain regarding its efficacy. Here we studied serologic responses in 145 patients …

[HTML][HTML] Prevention of Oncogenic Gammaherpesvirinae (EBV and HHV8) Associated Disease in Solid Organ Transplant Recipients

A Atamna, D Yahav, C Hirzel - Transplant International, 2023 - frontierspartnerships.org
Long-term risk for malignancy is higher among solid organ transplant (SOT) recipients
compared to the general population. Four non-hepatitis viruses have been recognized as …